CStone Pharmaceuticals’ Sugemalimab bags UK nods for Stage III NSCLC
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The innovative eyedrop targets inflammation and pain following ocular surgery
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Under the deal, Quiver will receive an undisclosed advance payment and research support
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
Subscribe To Our Newsletter & Stay Updated